Welcome to our dedicated page for National Resh news (Ticker: NRC), a resource for investors and traders seeking the latest updates and insights on National Resh stock.
NRC Health reports developments in healthcare experience improvement solutions for hospitals and health systems. Its updates cover products and services such as Patient Experience, Market Insights, Reputation, Leader Rounding, and The Governance Institute, a service that provides governance research, education, assessments, conferences, and advisory resources for not-for-profit hospital and health system boards.
Company news commonly includes quarterly operating results, Total Recurring Contract Value disclosures tied to renewable contracts, cash flow and adjusted performance measures, health system partnership expansions, online reputation and consumer insight initiatives, industry recognition, governance publications, and capital allocation actions such as share repurchase authorizations.
National Research Corporation (NASDAQ:NRC) announced an online web simulcast of its 2022 fourth quarter earnings conference call, scheduled for February 15, 2023, at 11:00 a.m. Eastern Time. Results will be released after market close on February 14, 2023. A 30-day online replay will be available post-broadcast. The webcast can be accessed at this link. NRC Health, with over 40 years of experience, focuses on enhancing healthcare organizations' understanding of their customers to improve experiences and foster trust.
NRC Health (NASDAQ:NRC) has declared a quarterly cash dividend of $0.12 per share, payable on January 13, 2023. Shareholders of record by December 30, 2022 will receive this payment. NRC Health focuses on enhancing patient experiences and relationships in healthcare, utilizing proprietary methods and a holistic approach.
NRC Health reported its third-quarter 2022 results, revealing revenue of $37.7 million, slightly down from $37.8 million in Q3 2021. The company’s net income declined to $8.3 million from $9.7 million year-over-year, leading to a decrease in diluted earnings per share, which fell to $0.33 from $0.38. Despite revenue growth from core offerings, the overall revenue was flat due to the phasing out of Canadian operations and a decline in non-core offerings. Increased operating expenses were attributed to investments in innovation and marketing. Dividends paid amounted to $5.9 million.
NRC Health's recent study reveals a significant disparity in trust levels between local healthcare providers and government entities during the COVID-19 pandemic. The research indicates that patients' language preferences notably influence their trust in healthcare providers, with English speakers 29% more likely to express strong trust. Additionally, trust in local healthcare systems rose from 20.7% to 35.8% from April 2020 to August 2022, while federal trust waned. Notably, trust levels are politically mixed across U.S. counties, challenging the narrative that political affiliation heavily influences provider trust.
On October 19, 2022, National Research Corporation (NASDAQ: NRC) announced an online web simulcast for its third quarter earnings conference call, scheduled for November 2, 2022, at 11:00 a.m. ET. The earnings results will be released after market close on November 1, 2022. A live audio webcast will be accessible via their website, with a replay available for 30 days after the event. NRC has a longstanding commitment to enhancing healthcare experiences through its proprietary methods and holistic approach.
NRC Health, a leader in personalized healthcare solutions, has announced its sponsorship of the Creative Learning Event Series organized by the Society for Participatory Medicine (SPM). This year-long initiative aims to enhance patient-provider relationships and promote equity in healthcare. The first event will be held on October 20, 2022, in Boston, focusing on access to care in underserved communities. NRC Health's support aligns with its mission of achieving Human Understanding, emphasizing collaboration among patients and healthcare professionals.
NRC Health announced a quarterly cash dividend of $0.24 per share, payable on October 14, 2022, to shareholders on record by September 30, 2022. This decision reflects NRC Health's ongoing commitment to returning value to its investors. With over 40 years of experience, NRC Health focuses on enhancing healthcare experiences and building trust within organizations through innovative methods and skilled associates.
NRC Health announced the winners of its 2022 Consumer Loyalty Awards and Excellence in Patient Experience Awards. This year, top hospitals were acknowledged for exceptional patient experiences amidst ongoing healthcare challenges post-pandemic. The Consumer Loyalty Awards spotlighted the top 100 healthcare facilities focusing on cultivating long-lasting loyalty, with ten facilities designated as Best-In-Class. The Excellence in Patient Experience Awards recognized hospitals for their commitment to improving patient care, based on Net Promoter Scores from patient surveys.
NRC Health announced its new role as a Diamond Supporting Partner with The Beryl Institute, emphasizing a commitment to enhancing patient experience through collaboration. This partnership aims to provide resources and opportunities for healthcare organizations to better serve patients. Helen Hrdy, Chief Growth Officer, underscored the critical need for patient-centered care. NRC Health has actively supported The Beryl Institute through past events and will now contribute to expanding the community's content and access to resources for members globally.
On August 2, 2022, National Research Corporation (NASDAQ:NRC) reported a 2% increase in Q2 2022 revenue, totaling $37.3 million, compared to $36.4 million in Q2 2021. However, operating income fell by 6% to $11.5 million, with net income decreasing to $8.3 million from $8.9 million. Diluted earnings per share also declined to $0.33. The company secured its first contract for the Human Understanding Program with Novant Health and continues to prioritize organic growth, despite challenges from discontinued offerings impacting revenue growth.